Recent advances in stability studies of carbapenems

Current Pharmaceutical Analysis

Volumn 7, Issue 4, 2011, Pages 213-227

  Cielecka Piontek, Judyta ^a   Michalska, Katarzyna ^b   Zalewski, Przemysław ^a   Jelińska, Anna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b NATIONAL MEDICINES INSTITUTE   (Poland)

Author keywords

Carbapenems; Related substances; Stability in aqueous solutions and in solid state; Stability indicating analytical method (SIAMs)

Indexed keywords

BIAPENEM; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; PANIPENEM; PIPERAZINEDIONE; PYRROLE DERIVATIVE; SOLVENT;

AQUEOUS SOLUTION; ARTICLE; CHEMICAL STRUCTURE; CHROMATOGRAPHY; DRUG DEGRADATION; DRUG DETERMINATION; DRUG DOSAGE FORM; DRUG HYDROLYSIS; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; PH; PRIORITY JOURNAL; TEMPERATURE; THERMODYNAMICS;

EID: 80053466631     PISSN: 15734129     EISSN: 1875676X     Source Type: Journal    
DOI: 10.2174/157341211797457989     Document Type: Article

References (80)

1. Norrby, S. Carbapenems. Med. Clin. North Am., 1995, 79, 745-759.
2. Zhanel, G.; Wiebe, R.; Dialy, L.; Thomson, K.; Rubistein E.; Hoban, D.; Noreddin, A.; Karlowsky, J. Comparative review of the carbapenems. Drugs, 2007, 67, 1027-1052.
3. Hurt, M.; Lamb, H. Meropenem: a review of its use in patients in intensive care. Drugs, 2000, 59, 653-680.
4. Nicolau, D.P. Carbapenems: a potent class of antibiotics. Expert Opin. Pharmacother., 2008, 9, 23-37.
5. Edwards, J.; Bett, M. Carbapenems: the pinnacle of the β -lactam antibiotics or room for improvement. J. Antimicrob. Chemother., 2000, 45, 1-4.
6. Coulton, S.; Hunt, E. Recent advances in the chemistry and biology of carbapenems antibiotics. Prog. Med. Chem., 1996, 33, 99-145.
7. Bonfiglio, G.; Russo, G.; Nicoletti, G. Recent developments in carbapenems. Expert Opin. Investig. Drugs, 2002, 11, 529-544.
8. Edwards, S.; Emmas, C.; Campbell, H. Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections. Curr. Med. Res. Opin., 2005, 21, 785-794.
9. Goa, K.; Noble, S. Panipenem/Betamipron. Drugs, 2003, 63, 913-925.
10. Sader, H.; Gales, A. Emerging strategies in infectious diseases. Drugs, 2001, 61, 553-564.
11. Curran, M.; Simpson, D.; Perry, C. Ertapenem: a review of its use in the management of bacterial infections. Drugs, 2003, 63, 1855-1878.
12. Hammond, M. Ertapenem: a group 1 carbapenem with distinct antibacterial and pharmacological properties. J. Antimicrob. Chemother., 2004, 53(Suppl. S2), ii7-ii9.
13. Motyl, M.; Mixson, L.; Friendland, I.; Gail, L.; Woods, M. Ertapenem: a pareteral, long-acting carbapenem. Clin. Microbiol. Newslett., 2003, 25, 89-95.
14. Walsh, F. Doripenem: a new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities. Ther. Clin. Risk Manag., 2007, 3, 789-794.
15. Perry, C.; Ibbotson, T. Biapenem. Drugs, 2002, 62, 2221-2234.
16. Deshpande, A.D.; Baheti, K.G.; Chatterjee, N.R. Degradation of β-lactam antibiotics. Curr. Sci., 2004, 87, 1684-1695.
17. Labro, M. Antibacterial agents-phagocytes: new concepts for old in immunomodulation. Int. J. Antimicrob. Agents, 1998, 10, 11-21.
18. Gruchalla, R.S.; Pirmohamed, M. Clinical practice: antibiotic allergy. N. Eng. J. Med. 2006, 354, 601-609.
19. Prescott, W.; Depestel, D.; Ellis, J.; Regal, R. Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy. Clin. Infect. Dis., 2004, 38, 1102-1107.
20. Sodhi, M.; Axtell, S.; Callahen, J.; Shekar, R. Is it safe to use carbapenems in patients with a history of allergy to penicillin? J. Antimicrob. Chemother., 2004, 54, 1155-1157.
21. Bradley, J.S.; Garau, J.; Lode, H.; Rolston, K.V.I; Wilson, S.E.; Quinn, J.P. Carbapenems in clinical practice: a guide to their use in serious infection. Int. J. Antimicrob. Agents, 1999, 11, 93-100.
22. Niwa, T.; Nakamura, A.; Kato, T.; Kutsuna, T.; Katou, K.; Morita, H.; Kojima, Y.; Itoh, M. Pharmacokinetic study of pleural fluid penetration of carbapenem antibiotic agents in chemical pleurisy. Resp. Med., 2006, 100, 324-331.
23. Norrby, S. Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis. J. Antimicrob. Chemother., 2000, 45, 5-7.
24. ICH, Stability testing of new drug substances and products. In: Proceedings of International Conference on Harmonization. IFPMA, Geneva, 2000.
25. ICH, Impurities in new drug products. In: Proceedings of International Conference on Harmonization 2006.
26. Hong, D.; Shah, D. Development and Validation of HPLC Stability-Indicating Assays. In: Drug Stability: Principles and Practices; Carstensen, J.T., Rhodes, C.T., Eds.; Marcel Dekker: New York, 2000, 329.
27. Sehrawat, R.; Maithani, M.; Singh, R. Regulatory aspects in development of stability-indicating methods: a review. Chromatographia, 2010, 72, 1-6.
28. Bakshi, M.; Singh, S. Development of validated stability-indicating assay methods-critical review. J. Pharm. Biomed. Anal., 2002, 28, 1011-1040.
29. ICH, Guidance on specific aspects of regulatory genotoxicity tests for pharmaceuticals. In: Proceedings of International conference on Harmonization, 1995.
30. Cielecka-Piontek, J.; Michalska, K.; Zalewski, P.; Zasada, S. Comparative review of analytical techniques for determination of carbapenems. Curr. Anal. Chem., 2011 (under review)
31. Smith, G.B.; Dezeny, G.; Douglas, A. Stability and kinetics of degradation of imipenem in aqueous solution. J. Pharm. Sci., 1990, 79, 732-740.
32. Mendez, R.; Alemany, T.; Martin-Villacort, J. Catalytic effect of buffers on degradation of imipenem (N-formimidoylthienamycin) in aqueous solution. Chem. Pharm. Bull., 1991, 39, 831-835.
33. Abdel-Moety, E.; Elragehy, N.; Hassan, N.; Rezk, M. Selective determination of ertapenem and imipenem in the presence of their degradants. J. Chrom. Sci., 2010, 48, 624-630.
34. Forsyth, R.; Ip, D. Determination of imipenem and cilastatin sodium in primaxin ® by first order derivative ultraviolet spectrophotometry. J. Pharm. Biomed. Anal., 1994, 12, 1243-1248.
35. Musson, D.; Hajdu, R.; Bayne, W.; Rogers, J. Quantification of imipenem's primary metabolite in plasma by postcolumn chemical rearrangement and UV detection. Pharm. Res., 1991, 8, 33-39.
36. Ito, N.; Suzuki, M.; Kusai, A.; Takayama, K. Effect of initial concentration on stability of panipenem in aqueous solution. Chem. Pharm. Bull., 2005, 53, 323-327.
37. Ito, N.; Suzuki, M.; Kusai, A.; Takayama, K. Isomerization kinetics of panipenem in aqueous solution. Chem. Pharm. Bull., 2005, 53, 537-540.
38. Ozkan, Y.; Kucukguzel, I.; Ozkan, S.; Aboul-Enein, H.Y. A rapid, sensitive high performance liquid chromatographic method for the determination of meropenem in pharmaceutical dosage form, human serum and urine. Biomed. Chrom., 2001, 15, 263-266.
39. Mendez, A.S.; Dalomo, J.; Steppe, M.; Schapoval, E.E. Stability and degradation kinetics of meropenem in powder for injection and reconstituted samples. J. Pharm. Biomed. Anal., 2006, 41, 1363-1366.
40. Takeuchi, Y.; Sungawa, M.; Isobe, Y.; Hamazume, Y.; Noguchi, T. Stability of a 1-beta-methylcarbapenem antibiotic, meropenem in aqueous solution. Chem. Pharm. Bull., 1994, 43, 659-692.
41. Takeuchi, Y.; Takebayashi, Y.; Sunagawa, M.; Isobe, Y.; Hamazume, Y.; Uemura, A.; Noguchi, T. The stability of a novel carbapenem antibiotic, meropenem (SM-7338), in a solid state formulation for injection. Chem. Pharm. Bull., 1993, 41, 1998-2002.
42. Elragehy, N.A.; Abdel-Moety, E.M.; Hassan, N.Y.; Rezk, M.R. Stability-indicating determination of meropenem in presence of its degradation product. Talanta, 2008, 77, 28-32.
43. Patel, R.P.; Cook, SE. Stability of meropenem in intravenous solutions. Am. J. Health-syst. Pharm., 1997, 54, 412-421.
44. Grant, E.; Zhong, M.; Ambrose, P.; Nicolau, D.; Nightingale, Ch.; Quintilliani, R. Stability of meropenem in a portable infusion device in a cold pouch. Am. J. Health-Syst. Pharm., 2000, 57, 992-995.
45. Jaruratanasirikul, S.; Sriwiriyajan, S. Stability of meropenem in normal saline solution after storage at room temperature. Southeast Asian J. Trop. Med. Pub. Health, 2003, 34, 627-629.
46. Cai, S.Y.; Hu, Ch. Chromatographic determination of polymerized impurities in meropenem. J. Pharm. Biomed. Anal., 2005, 37, 585-589.
47. Kramer, I. Stability of meropenem in elastomeric portable infusion devices. Eur. Hosp. Pharm., 1997, 3, 168-171.
48. Smith, D.L.; Bauer, S.M.; Nicolau, D.P. Stability of meropenem in polyvinyl chloride bags and an elastometric infusion device. Am. J. Health-Syst. Pharm., 2004, 61, 1682-1685.
49. Berthoin, K.; Duff, C.S.; Marchand-Brynaert, J.; Carryn, S.; Tulkens, P.M. Stability of meropenem and doripenem solutions for administration by continuous infusion. J. Antimicrob. Chemother., 2010, 7, 1073-1075.
50. Cielecka-Piontek, J.; Zajac, M.; Jelińska, A. A comparison of the stability of ertapenem and meropenem in pharmaceutical preparations in solid state. J. Pharm. Biomed. Anal., 2008, 46, 52-57.
51. Lefeuvre, S.; Venisse, N.; Marchand, S.; Bachelet, M.; Couet, W. A simple and sensitive liquid chromatography-tandem mass spectrometry assay for the quantification or ertapenem in microdialysate. J. Chromatogr. B., 2008, 862, 242-245.
52. Sajonz, P.; Natishan, T.; Wu, Y.; McGachy, N.; DeTora, D. Development and validation of a sensitive and robust wipe-test method for the detection and quantification of the antibiotic ertapenem and its primary degradates in a pharmaceutical manufacturing environment. J. Liq. Chromatogr. Relat. Technol., 2005, 28, 713-725.
53. Sajonz, P.; Wu, Y.; Natishan, T.K.; McGachy, N.T.; Detora, D. Challenges in the analytical method development and validation for an unstable active pharmaceutical ingredient. J. Chromtogr. Sci., 2006, 44, 132-140.
54. Sajonz, P.; Natishan, T.; Wu, Y.; Williams, J.; Pipik, B.; DiMichele, L.; Novak, T.; Pitzenberger, I.; Dubost, D.; Almarsson, O. Preparation, isolation, and characterization of dimeric degradation products of the 1β-methylcarbapenem antibiotics, ertapenem. J. Liq. Chromatogr. Relat. Technol., 2001, 24, 2999-3015.
55. Patel, R.P.; Cook, S.E. Stability of meropenem in intravenous solutions. Am. J. Health-Syst. Pharm., 1997, 54, 412-421.
56. Zajac, M.; Cielecka-Piontek, J.; Jelińska, A. Stability of ertapenem in aqueous solutions. J. Pharm. Biomed. Anal., 2007, 43, 445-449.
57. McQuade, M.; Nostrand, V.; Schariter, J.; Kanike, J.; Forsyth, R. Stability and compatibility of reconstituted ertapenem with commonly used i.v. infusion and coinfusion solutions. Am. J. Health-Syst. Pharm., 2004, 61, 38-45.
58. Hassan, N.; Abdel-Moety, E.; Elragehy, N.; Rezk, M. Selective determination of ertapenem in the presence of its degradation product. Spectrochim. Acta Part A, 2009, 72, 915-921.
59. Zajac, M.; Cielecka-Piontek, J.; Jelińska, A. Development and validation of UV spectrophotometric and RP.HPLC methods for determination of ertapenem during stability studies. Chem. Anal., 2006, 51, 761-768.
60. Michalska, K.; Pajchel, G.; Tyski, S. Different sample stacking strategies for the determination of ertapenem and its impurities by micellar electrokinetic chromatography in pharmaceutical formulation. J. Chromatogr. A, 2009, 1216, 2934-2942.
61. Cielecka-Piontek, J.; Krause, A.; Milewski, M.; Lunzer, A.; Jelińska, A.; Zalewski, P. Stability-indicating LC method for the determination of biapenem in the presence of degradation products, 36th International Symposium High-Performance Liquid Phase Separations and Related Techniques, 19-23 June 2011, Hungary, P2-G-735-WE.
62. Cielecka-Piontek, J.; Jelińska, A.; Dołhań, A.; Nasreen, A.; Shampa, I. Kinetic and thermodynamic analysis of degradation of doripenem in solid state. Conference "Progress in the evaluation of quality of pharmaceutical substances" Poznan, Poland 2010, 17-18 July, 80.
63. Cielecka-Piontek, J.; Jelińska, A. Catalytic effect of buffers on the degradation of doripenem in aqueous solutions. Chem. Mater. Sci., 2011, 102, 37-47, DOI: 10.1007/s11144-010-0249-0; [E-pub ahead of print].
64. Berthoin, K.; Duff, C.S.; Marchand-Brynaert, J.; Carryn, S.; Tulkens, P.M. Stability of meropenem and doripenem solutions for administration by continuous infusion. J. Antimicrob. Chemother., 2010, 65, 1073-1075.
65. Crandon, J.; Sutherland, Ch.; Nicolau, D. Stability of doripenem in polyvinyl chloride bags and elastomeric pumps. Am. J. Health-Syst. Pharm., 2010, 15, 1539-1544.
66. Sutherland, Ch.; Nicolau, D. Development of an HPLC method for the determination of doripenem in human and mouse serum. J. Chrom. B., 2007, 853, 123-126.
67. Psathas, P.; Kuzmission, A.; Ikeda, K.; Yasuo, S. Stability of doripenem in vitro in representative infusion solutions and infusion bags. Clin. Ther., 2008, 30, 2075-2083.
68. Cielecka-Piontek, J.; Jelińska, A. The UV-derivative spectrophotometry for the determination of doripenem in the presence of its degradation products. Spectrochim. Acta Part A, 2010, 77, 554-557.
69. Xia, M.; Hang, T.; Zhang, F.; Li, X.; Xu, X. The stability of biapenem and structural identification of impurities in aqueous solution. J. Pharm. Biomed. Anal., 2009, 49, 937-944.
70. Cielecka-Piontek, J.; Lunzer, A.; Jelińska, A. Stability-indicating derivative spectrophotometry method for the determination of biapenem in the presence of its degradation products. Cent. Eur. J. Chem., 2011, 9, 35-40.
71. Michalska, K.; Pajchel, G.; Tyski, S. Determination of doripenem and related subsntances in medicinal product using capillary electrophoresis. J. Sep. Sci., 2011, 34, 1-8.
72. Mendez, A.S.; Steppe, M.; Schapoval, E.E. Validation of HPLC and UV spectrophotometric methods for the determination of meropenem pharmaceutical dosage form. J. Pharm. Biomed. Anal., 2003, 33, 947-954.
73. Fernandez-Torres, R.; Navarro, M.; Lopez, B.; Mochon, M.; Sanchez, J. Urea as new stabilizing agent for imipenem determination. Electrochemical study and determination of imipenem and its primary metabolite in human urine. Talanta, 2008, 77, 241-248.
74. Hilali, A.; Jiménez, J.C.; Callejón, M.; Bello, M.A.; Guiraúm, A. Electrochemical study of imipenem's primary metabolite at the mercury electrode. Voltammetric determination in urine. J. Pharm. Biomed. Anal., 2005, 38, 768-775.
75. Mendez, A.; Chagastelles, P.; Palma, E.; Nardi, N.; Schapoval, E. Thermal and alkaline stability of meropenem: degradation products and cytotoxicity. Inter. J. Pharm., 2008, 350, 95-102
76. Vailaya, A.; Sajonz, P.; Sudah, S.; Capodanno, V.; Helmy, R.; Antia, F. Exploiting pH mismatch in preparative high-performance liquid chromagraphic recovery of ertapenem from mother liquor streams. J. Chromatogr. A, 2005, 1079, 80-91.
77. Keel, R.; Sutherland, Ch.; Crandon, J. Stability of doripenem, imipenem and meropenem at elevated room temperature. Int. J. Antimocrob. Agents, 2011, 37, 184-185.
78. Mendez, R.; Alemany, T.; Martin-Villacorta, J. Catalysis of hydrolysis and aminolysis of non-classical β-lactam antibiotics by metal ions and metal chelates. Chem. Pharm. Bull., 1992, 43, 3228-3233.
79. Trissel, L.; Xu, Q. Stability of imipenem-cilastatin sodium in autodose infusion system bags. Hosp. Pharm., 2003, 38, 130-134.
80. Mendez, A.; Weisheimer, V.; Oppe, T.; Steppe, M.; Schapoval, E. Microbiologica assay for the determination of meropenem in pharmaceutical dosage form. J. Pharm. Biomed. Anal., 2005, 37, 649-653.